

Naglazyme® (galsulfase) (Intravenous)

Effective Date: 01/01/2020

Review Date: 12/13/2019, 1/29/2020, 5/27/2021, 2/17/2022, 1/19/2023, 12/07/2023, 01/04/2024, 4/30/2025, 03/03/2026

Scope: Medicaid, Commercial, Medicare

I. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

II. Dosing Limits

A. Max Units (per dose and over time) [HCPCS Unit]:

- 115 billable units every 7 days

III. Summary of Evidence

Naglazyme is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome) and has been shown to improve walking and stair-climbing capacity. In a 24-week randomized, double-blind, multicenter, placebo-controlled clinical trial, 38 patients aged 5 to 29 years with MPS VI received 1 mg.kg Naglazyme or placebo once-weekly. The Naglazyme treatment group demonstrated improvements in walking distance by 83 meters in the 12-minute walk test ($p=0.025$) and increased stair-climbing capacity by 4.7 stairs/min compared to placebo treatment group. In a long-term extension study (up to 96 weeks and an additional 240-week open-label period) Naglazyme demonstrated sustained and continued functional improvements. Naglazyme also reduced urinary GAG levels by $\geq 50\%$ in 95% of patients, indicated significant biochemical response. Other improvements included increased forced vital capacity (FVC), decrease urinary GAG levels, and reduced hepatomegaly and splenomegaly in patients with MPS VI. The most common adverse reaction requiring intervention is infusion-related reactions (pyrexia, chills, rash, urticaria, dyspnea, nausea/vomiting), with hypersensitivity reactions (including anaphylaxis) also being reported with early and after prolonged therapy.

IV. Initial Approval Criteria^{1,2,4,5,6}

Coverage is provided in the following conditions:

Medicare members who have previously received this medication within the past 365 days are not subject to Step Therapy Requirements.

- Member is 5 years of age or older; **AND**
- Documented baseline 12-minute walk test (12-MWT), 3-minute stair climb test, and/or pulmonary function tests (e.g., FEV1, etc.); **AND**
- Documented baseline value for urinary glycosaminoglycan (uGAG); **AND**
- Therapy is being used to treat non-central nervous system manifestations of the disease and member does not have severe, irreversible cognitive impairment; **AND**

Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome) †

- Member has a definitive diagnosis of MPS VI as confirmed by the following:
 - Detection of pathogenic mutations in the *ARSB* gene by molecular genetic testing; **OR**
 - Arylsulfatase B (ASB) enzyme activity of <10% of the lower limit of normal in cultured fibroblasts or isolated leukocytes; **AND**
 - Member has normal enzyme activity of a different sulfatase (excluding patients with Multiple Sulfatase Deficiency [MSD]); **AND**
 - Member has an elevated urinary glycosaminoglycan (uGAG) level (i.e., dermatan sulfate or chondroitin sulfate) defined as being above the upper limit of normal by the reference laboratory;
- † FDA-approved indication(s)

V. Renewal Criteria^{1,2,4,5,6}

Authorizations can be renewed based on the following criteria:

- Member continues to meet initial and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: anaphylaxis and hypersensitivity reactions, immune-mediated reactions, acute respiratory complications associated with administration, acute cardiorespiratory failure, severe infusion reactions, spinal or cervical cord compression, etc.; **AND**
- Disease response with treatment as defined by improvement or stability from pre-treatment baseline by the following:
 - Reduction in uGAG levels; **AND**
 - Improvement in or stability of 12-minute walk test compared (12-MWT); **OR**
 - Improvement in or stability of 3-minute stair climb test (3-MSCT); **OR**

- Improvement in or stability of pulmonary function testing (e.g., FEV1, etc.)

VI. Dosage/Administration^{1,4}

Indication	Dose
Mucopolysaccharidosis VI(MPS VI) (Maroteaux-Lamy Syndrome)	1 mg/kg administered as an intravenous (IV) infusion once a week

VII. Billing Code/Availability Information

HCPCS Code:

J1458 – Injection, galsulfase, 1 mg; 1 billable unit = 1 mg

NDC:

Naglazyme 5 mg per 5 mL solution; single-use vial: 68135-0020-xx

VIII. References

1. Naglazyme [package insert]. Novato, CA; BioMarin Pharmaceutical Inc.; September 2024. Accessed February 2026.
2. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. *Pediatrics*. 2007 Aug;120(2):405-18.
3. Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. *Genet Mol Biol*. 2010 Oct;33(4):589-604. Epub 2010 Dec 1.
4. Vairo F, Federhen A, Baldo G, et al. Diagnostic and treatment strategies in mucopolysaccharidosis VI. *Appl Clin Genet*. 2015 Oct 30;8:245-55.
5. Valaannopoulos V, Nicely H, Harmatz P, et al. Mucopolysaccharidosis VI. *Orphanet J Rare Dis*. 2010; 5: 5.
6. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. *J Pediatr*. 2006 Apr;148(4):533-539.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
E76.29	Other mucopolysaccharidoses

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Articles may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/Article): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC

Policy Rationale:

Naglazyme was reviewed by the Neighborhood Health Plan of Rhode Island Pharmacy & Therapeutics (P&T) Committee. Neighborhood adopted the following clinical coverage criteria to ensure that its members use Naglazyme according to Food and Drug Administration (FDA) approved labeling and/or relevant clinical literature. Neighborhood worked with network prescribers and pharmacists to draft these criteria. These criteria will help ensure its members are using this drug for a medically accepted indication, while minimizing the risk for adverse effects and ensuring more cost-effective options are used first, if applicable and appropriate. For Medicare members, these coverage criteria will only apply in the absence of National Coverage Determination (NCD) or Local Coverage Determination (LCD) criteria. Neighborhood will give individual consideration to each request it reviews based on the information submitted by the prescriber and other information available to the plan.